PL3362094T3 - Kombinacja zawierająca związek tioaminoestrowy lub jego farmaceutycznie dopuszczalną sól oraz związek mogący zwiększyć poziom h2o2 w komórkach nowotworowych osobnika - Google Patents

Kombinacja zawierająca związek tioaminoestrowy lub jego farmaceutycznie dopuszczalną sól oraz związek mogący zwiększyć poziom h2o2 w komórkach nowotworowych osobnika

Info

Publication number
PL3362094T3
PL3362094T3 PL16784442T PL16784442T PL3362094T3 PL 3362094 T3 PL3362094 T3 PL 3362094T3 PL 16784442 T PL16784442 T PL 16784442T PL 16784442 T PL16784442 T PL 16784442T PL 3362094 T3 PL3362094 T3 PL 3362094T3
Authority
PL
Poland
Prior art keywords
combination
thioaminoester
trouble
cells
compound
Prior art date
Application number
PL16784442T
Other languages
English (en)
Polish (pl)
Inventor
Ismail Ceylan
Gerry QUASH
Mileidys PEREZ-ALEA
Guillaume Martin
Original Assignee
Advanced Biodesign
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Biodesign filed Critical Advanced Biodesign
Publication of PL3362094T3 publication Critical patent/PL3362094T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL16784442T 2015-10-15 2016-10-14 Kombinacja zawierająca związek tioaminoestrowy lub jego farmaceutycznie dopuszczalną sól oraz związek mogący zwiększyć poziom h2o2 w komórkach nowotworowych osobnika PL3362094T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15306650 2015-10-15
PCT/EP2016/074682 WO2017064241A1 (en) 2015-10-15 2016-10-14 Combination comprising an aminothiolester compound or a pharmaceutically acceptable salt thereof and a compound able to increase the h2o2 level in cancer cells of a subject
EP16784442.2A EP3362094B1 (en) 2015-10-15 2016-10-14 Combination comprising an aminothiolester compound or a pharmaceutically acceptable salt thereof and a compound able to increase the h2o2 level in cancer cells of a subject

Publications (1)

Publication Number Publication Date
PL3362094T3 true PL3362094T3 (pl) 2021-10-11

Family

ID=54360386

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16784442T PL3362094T3 (pl) 2015-10-15 2016-10-14 Kombinacja zawierająca związek tioaminoestrowy lub jego farmaceutycznie dopuszczalną sól oraz związek mogący zwiększyć poziom h2o2 w komórkach nowotworowych osobnika

Country Status (21)

Country Link
US (1) US10406125B2 (cg-RX-API-DMAC10.html)
EP (1) EP3362094B1 (cg-RX-API-DMAC10.html)
JP (1) JP7062592B2 (cg-RX-API-DMAC10.html)
CN (1) CN108348612A (cg-RX-API-DMAC10.html)
AR (1) AR106351A1 (cg-RX-API-DMAC10.html)
CA (1) CA3001201C (cg-RX-API-DMAC10.html)
CY (1) CY1123916T1 (cg-RX-API-DMAC10.html)
DK (1) DK3362094T3 (cg-RX-API-DMAC10.html)
ES (1) ES2870508T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20210358T1 (cg-RX-API-DMAC10.html)
HU (1) HUE054247T2 (cg-RX-API-DMAC10.html)
IL (1) IL258658B (cg-RX-API-DMAC10.html)
LT (1) LT3362094T (cg-RX-API-DMAC10.html)
MX (1) MX377725B (cg-RX-API-DMAC10.html)
PL (1) PL3362094T3 (cg-RX-API-DMAC10.html)
PT (1) PT3362094T (cg-RX-API-DMAC10.html)
RS (1) RS61572B1 (cg-RX-API-DMAC10.html)
SI (1) SI3362094T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202100270T1 (cg-RX-API-DMAC10.html)
WO (1) WO2017064241A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201802400B (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102941434B1 (ko) * 2019-07-31 2026-03-19 어드방스드 비오디자인 아미노티올에스터 화합물 및 이의 용도
FR3119314B1 (fr) * 2021-01-29 2025-01-10 Advanced Biodesign Nanocapsule lipidique comprenant au moins un composé aminothiolester ou un de ses dérivés pharmaceutiquement acceptable
EP4035666A1 (en) * 2021-01-29 2022-08-03 Advanced Biodesign Aminothiolester compound or derivative thereof for use as an immunomodulatory agent
WO2025229179A1 (en) * 2024-05-03 2025-11-06 Advanced Biodesign Use of aminothiolester compounds in combination with hypomethylating agents (hma) for the prevention and treatment of cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2777001B1 (fr) * 1998-04-01 2000-06-09 Cird Galderma Derives de l'acide 6,8-dimercaptooctanoique substitues en 6-s et/ou en 8-s par le radical (3-methylthiopropanoyl) et compositions pharmaceutiques destinees au traitement des tumeurs cancereuses
FR2809727B1 (fr) * 2000-05-31 2002-07-26 Galderma Res & Dev Nouveaux composes aminothiolesters, compositions pharmaceutiques et cosmetiques les contenant et utilisations

Also Published As

Publication number Publication date
RS61572B1 (sr) 2021-04-29
IL258658A (en) 2018-06-28
US10406125B2 (en) 2019-09-10
WO2017064241A1 (en) 2017-04-20
MX377725B (es) 2025-03-11
HK1251477A1 (en) 2019-02-01
JP2018531995A (ja) 2018-11-01
DK3362094T3 (da) 2021-03-01
HRP20210358T1 (hr) 2021-04-16
HUE054247T2 (hu) 2021-08-30
SI3362094T1 (sl) 2021-04-30
LT3362094T (lt) 2021-05-10
CN108348612A (zh) 2018-07-31
JP7062592B2 (ja) 2022-05-06
EP3362094A1 (en) 2018-08-22
IL258658B (en) 2021-04-29
CY1123916T1 (el) 2022-05-27
CA3001201C (en) 2023-07-11
PT3362094T (pt) 2021-04-15
AR106351A1 (es) 2018-01-03
SMT202100270T1 (it) 2021-07-12
MX2018004381A (es) 2018-05-11
ES2870508T3 (es) 2021-10-27
US20180303773A1 (en) 2018-10-25
BR112018007480A2 (en) 2018-10-23
CA3001201A1 (en) 2017-04-20
EP3362094B1 (en) 2021-02-17
ZA201802400B (en) 2020-01-29

Similar Documents

Publication Publication Date Title
IL261433A (en) Active data-aware storage manager
MA47419A (fr) Mousqueton à double verrouillage
GEAP201914688A (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
IL256455B (en) Phenoxyhalogenphenylamidines and the use thereof as fungicides
PL3322424T3 (pl) Zastosowanie centralnych limfocytów t pamięci przeciwko stronie trzeciej
HUE060120T2 (hu) Herbicidként aktív 4-difluormetilbenzoilamid
IL272859A (en) Salts of ribociclib and their solid forms
GB201504971D0 (en) Memory management
GB201503505D0 (en) Memory management
GB201620954D0 (en) Memory management
ZA201901543B (en) Heterocyclic compound, and harmful-arthropod-controlling agent containing same
IL256722B (en) Self belay arrangement for climbing applications
EP3493489A4 (en) FUSE SAFETY BETWEEN AN ACTIVE PSEUDODRAHT AND A STANDBY PSEUDO WIRE
GB201602865D0 (en) Memory management
GB2536199B (en) Memory management
MA47569A (fr) Composé guanidine et bactéricide
PL3231417T3 (pl) Odporna na składowanie kompozycja oftalmiczna
ZA201802400B (en) Combination comprising an aminothiolester compound or a pharmaceutically acceptable salt thereof and a compound able to increase the h2o2 level in cancer cells of a subject
PL3338929T3 (pl) Płytka skrawająca
AU201617038S (en) Storage case
DK3522424T3 (da) Soft-buffer-håndtering med begrænset hukommelsesadgangsbåndbredde
IL269679A (en) Eye devices and methods of using them
AU201713377S (en) Storage can
JP2017012034A5 (cg-RX-API-DMAC10.html)
TWM533997U (en) Active type escape equipment